DK2740796T3 - Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer - Google Patents
Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer Download PDFInfo
- Publication number
- DK2740796T3 DK2740796T3 DK12820596.0T DK12820596T DK2740796T3 DK 2740796 T3 DK2740796 T3 DK 2740796T3 DK 12820596 T DK12820596 T DK 12820596T DK 2740796 T3 DK2740796 T3 DK 2740796T3
- Authority
- DK
- Denmark
- Prior art keywords
- ser
- antibody
- gly
- gin
- thr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (22)
1. Antistof eller fragment deraf, som har immunologisk reaktivitet med et delvist CAPRIN-1-polypeptid bestående af aminosyresekvensen vist ved SEQ ID NO: 5.
2. Antistof eller fragment deraf ifølge krav 1, hvor antistoffet eller fragmentet deraf har cytotoksisk aktivitet mod en kræftcelle, der udviser et CAPRIN-1 -protein.
3. Antistof eller fragment deraf ifølge krav 1 eller 2, hvor antistoffet er et mo-noklonalt antistof.
4. Antistof eller fragment deraf ifølge krav 1 eller 2, hvor antistoffet er et poly-klonalt antistof.
5. Antistof eller fragment deraf ifølge et af kravene 1 til 4, hvor antistoffet er et humant antistof, et humaniseret antistof, et kimærisk antistof, et enkeltkædet antistof eller et multispecifikt antistof.
6. Antistof eller fragment deraf ifølge et af kravene 1 til 3 eller 5, som omfatter en variabel region med tung kæde omfattende komplementaritetsbestemmende regioner af SEQ ID NOs: 6, 7 og 8 og en variabel region med let kæde omfattende komplementaritetsbestemmende regioner af SEQ ID NOs: 10, 11 og 12, og har immunologisk reaktivitet med CAPRIN-1-proteinet.
7. Antistof eller fragment deraf ifølge et af kravene 1 til 3 eller 5, som omfatter en variabel region med tung kæde omfattende komplementaritetsbestemmende regioner af SEQ ID NOs: 16, 17 og 18 og en variabel region med let kæde omfattende komplementaritetsbestemmende regioner af SEQ ID NOs: 20, 21 og 22 og har immunologisk reaktivitet med CAPRIN-1-proteinet.
8. Antistof eller fragment deraf ifølge et af kravene 1 til 3 eller 5, som omfatter en variabel region med tung kæde omfattende komplementaritetsbestemmende regioner af SEQ ID NOs: 6, 7 og 8 og en variabel region med let kæ de omfattende komplementaritetsbestemmende regioner af SEQ ID NOs: 50, 51 og 52 og har immunologisk reaktivitet med CAPRIN-1-proteinet.
9. Antistof eller fragment deraf ifølge et af kravene 1 til 3 eller 5, som omfatter en variabel region med tung kæde omfattende komplementaritetsbestemmende regioner regioner af SEQ ID NOs: 55, 56 og 57 og en variabel region med let kæde omfattende komplementaritetsbestemmende regioner af SEQ ID NOs: 59, 60 og 61 og har immunologisk reaktivitet med CAPRIN-1 -proteinet.
10. Antistof eller fragment deraf ifølge et af kravene 1 til 3 eller 5, som omfatter en variabel region med tung kæde omfattende komplementaritetsbestemmende regioner af SEQ ID NOs: 55, 56 og 57 og en variabel region med let kæde omfattende komplementaritetsbestemmende regioner af SEQ ID NOs: 59, 64 og 61 og har immunologisk reaktivitet med CAPRIN-1-proteinet.
11. Antistof eller fragment deraf ifølge et af kravene 1 til 3 eller 5, som omfatter en variabel region med tung kæde omfattende komplementaritetsbestemmende regioner af SEQ ID NOs: 66, 67 og 68 og en variabel region med let kæde omfattende komplementaritetsbestemmende regioner af SEQ ID NOs: 70, 71 og 72 og har immunologisk reaktivitet med CAPRIN-1-proteinet.
12. Antistof eller fragment deraf ifølge et af kravene 1 til 3 eller 5, som omfatter en variabel region med tung kæde omfattende komplementaritetsbestemmende regioner af SEQ ID NOs: 74, 75 og 76 og en variabel region med let kæde omfattende komplementaritetsbestemmende regioner af SEQ ID NOs: 78, 79 og 80 og har immunologisk reaktivitet med CAPRIN-1-proteinet.
13. Antistof eller fragment deraf ifølge et af kravene 1 til 12, hvor antistoffet eller fragmentet deraf er konjugeret med et antitumormiddel.
14. Antistof eller fragment deraf ifølge et hvilket som helst af de foregående krav til anvendelse i en fremgangsmåde til behandling og/eller forebyggelse af cancer.
15. Antistof eller fragment deraf til anvendelse ifølge krav 14, hvor cancertypen er brystcancer, nyrecancer, pankreascancer, tyktarmscancer, lungecancer, hjernetumor, mavecancer, livmoderhalscancer, æggestokcancer, prosta-tacancer, urinblærecancer, spiserørscancer, leukæmi, lymfom, fibrosarkom, mastocytom eller melanom.
16. Farmaceutisk sammensætning omfattende antistoffet eller fragmentet deraf ifølge et kravene 1 til 13 som et aktivt stof.
17. Farmaceutisk sammensætning ifølge krav 16 til anvendelse i en fremgangsmåde til behandling og/eller forebyggelse af cancer.
18. Farmaceutisk sammensætning til anvendelse ifølge krav 17, hvor cancertypen er brystcancer, nyrecancer, pankreascancer, tyktarmscancer, lungecancer, hjernetumor, mavecancer, livmoderhalscancer, æggestokcancer, prostatacancer, urinblærecancer, spiserørscancer, leukæmi, lymfom, fibrosarkom, mastocytom eller melanom.
19. Farmaceutisk kombination omfattende en farmaceutisk sammensætning ifølge krav 16 og en farmaceutisk sammensætning, der omfatter et antitumormiddel.
20. Farmaceutisk kombination ifølge krav 19 til anvendelse i en fremgangsmåde til behandling og/eller forebyggelse af cancer.
21. Farmaceutisk sammensætning til anvendelse ifølge krav 20, hvor cancertypen er brystcancer, nyrecancer, pankreascancer, tyktarmscancer, lungecancer, hjernetumor, mavecancer, livmoderhalscancer, æggestokcancer, prostatacancer, urinblærecancer, spiserørscancer, leukæmi, lymfom, fibrosarkom, mastocytom eller melanom.
22. DNA, der koder antistoffet eller fragmentet deraf ifølge et af kravene 1 til 12.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011171300 | 2011-08-04 | ||
| PCT/JP2012/069862 WO2013018894A1 (ja) | 2011-08-04 | 2012-08-03 | 癌の治療及び／又は予防用医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2740796T3 true DK2740796T3 (da) | 2017-07-24 |
Family
ID=47629408
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17163690.5T DK3351630T3 (da) | 2011-08-04 | 2012-08-03 | Farmaceutisk sammensætning omfattende anti caprin-1-antistoffer til behandling og/eller forebyggelse af cancer |
| DK12820596.0T DK2740796T3 (da) | 2011-08-04 | 2012-08-03 | Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17163690.5T DK3351630T3 (da) | 2011-08-04 | 2012-08-03 | Farmaceutisk sammensætning omfattende anti caprin-1-antistoffer til behandling og/eller forebyggelse af cancer |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9273128B2 (da) |
| EP (2) | EP2740796B1 (da) |
| JP (1) | JP6070191B2 (da) |
| KR (1) | KR101979208B1 (da) |
| CN (1) | CN103717740B (da) |
| AU (1) | AU2012290957B2 (da) |
| BR (1) | BR112014002608A2 (da) |
| CA (1) | CA2844042C (da) |
| DK (2) | DK3351630T3 (da) |
| ES (2) | ES2634249T3 (da) |
| HU (2) | HUE033149T2 (da) |
| MX (1) | MX351682B (da) |
| PL (2) | PL3351630T3 (da) |
| PT (2) | PT2740796T (da) |
| RU (1) | RU2641260C2 (da) |
| WO (1) | WO2013018894A1 (da) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2519089C2 (ru) | 2008-08-05 | 2014-06-10 | Торэй Индастриз, Инк. | Способ обнаружения злокачественных опухолей |
| PT2322221E (pt) | 2008-08-05 | 2014-09-19 | Toray Industries | Composição farmacêutica para tratamento e prevenção de cancro |
| MX340017B (es) | 2010-02-04 | 2016-06-22 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| ES2691738T3 (es) | 2010-02-04 | 2018-11-28 | Toray Industries, Inc. | Agente farmacéutico para el tratamiento y/o la prevención de cáncer |
| HUE030103T2 (en) | 2010-02-04 | 2017-04-28 | Toray Industries | A pharmaceutical composition for the treatment and / or prevention of cancer |
| CA2788718C (en) | 2010-02-04 | 2019-05-21 | Shinichi Kobayashi | Caprin-1 antibody for treating and/or preventing cancer |
| WO2011096517A1 (ja) | 2010-02-04 | 2011-08-11 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| MX342291B (es) | 2010-02-04 | 2016-09-23 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| BR112014002614B1 (pt) | 2011-08-04 | 2022-09-20 | Toray Industries, Inc | Anticorpo ou um fragmento do mesmo, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica |
| CA2844038C (en) | 2011-08-04 | 2019-05-07 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| PL2740489T3 (pl) | 2011-08-04 | 2017-06-30 | Toray Industries, Inc. | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka trzustki |
| TR201808595T4 (tr) | 2011-08-04 | 2018-07-23 | Toray Industries | Kanser hastalıklarının tedavisi ve/veya profilaksisi için farmasötik bileşim. |
| EP2740795B1 (en) | 2011-08-04 | 2016-10-05 | Toray Industries, Inc. | Cancer treatment and/or prevention drug composition |
| HUE033149T2 (en) | 2011-08-04 | 2017-11-28 | Toray Industries | A pharmaceutical composition for the treatment and / or prevention of cancer |
| BR112014002616B1 (pt) | 2011-08-04 | 2022-01-18 | Toray Industries, Inc | Método para detectar câncer pancreático |
| HUE046788T2 (hu) | 2012-02-21 | 2020-03-30 | Toray Industries | Gyógyászati készítmény rák kezelésére és/vagy megelõzésére |
| BR112014021102A2 (pt) | 2012-02-21 | 2021-12-28 | Toray Industries | Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo |
| CN104169303B (zh) | 2012-02-21 | 2018-05-29 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| MX360211B (es) * | 2012-02-21 | 2018-10-24 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| HUE036425T2 (hu) | 2012-03-30 | 2018-07-30 | Toray Industries | Gyógyászati készítmény epehólyagrák kezelésére és/vagy megelõzésére |
| BR112014023937A2 (pt) | 2012-03-30 | 2018-04-17 | Toray Industries | composição farmacêutica, agente farmacêutico de combinação e método de tratamento |
| BR112015001102A2 (pt) | 2012-07-19 | 2018-09-04 | Toray Industries, Inc. | método de detecção de câncer, droga ou kit e método de seleção de droga terapêutica |
| WO2014014086A1 (ja) | 2012-07-19 | 2014-01-23 | 東レ株式会社 | 癌の検出方法 |
| KR102255616B1 (ko) | 2013-08-09 | 2021-05-25 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| CN108779497B (zh) * | 2016-03-14 | 2022-08-02 | 库雷梅塔治疗有限责任公司 | 足糖萼蛋白和tra-相关抗体、制备方法和作为抗癌治疗剂的用途 |
| EP3484518B1 (en) | 2016-07-07 | 2024-08-14 | The Board of Trustees of the Leland Stanford Junior University | Antibody adjuvant conjugates |
| US20200054762A1 (en) | 2016-10-28 | 2020-02-20 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
| EP3589641A1 (en) * | 2017-03-04 | 2020-01-08 | Kyoto University | Therapeutic peptides |
| WO2019189780A1 (ja) | 2018-03-30 | 2019-10-03 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| JP2022525594A (ja) | 2019-03-15 | 2022-05-18 | ボルト バイオセラピューティクス、インコーポレーテッド | Ｈｅｒ２を標的とする免疫結合体 |
| BR112022018157A2 (pt) | 2020-03-12 | 2022-10-25 | Toray Industries | Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método para o tratamento e/ou prevenção do câncer |
| BR112022018163A2 (pt) | 2020-03-12 | 2022-10-25 | Toray Industries | Medicamento para tratamento e/ou prevenção de câncer, agentes que aumentam a eficácia de droga de uma composição farmacêutica e método para tratar e/ou prevenir câncer |
| BR112022018166A2 (pt) | 2020-03-12 | 2022-10-25 | Toray Industries | Medicamento para tratamento e/ou prevenção de câncer, agentes que aumentam a eficácia de droga de uma composição farmacêutica e método para tratar e/ou prevenir câncer |
| CA3175129A1 (en) | 2020-03-12 | 2021-09-19 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| BR112022018161A2 (pt) | 2020-03-12 | 2022-10-25 | Toray Industries | Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método para o tratamento e/ou prevenção do câncer |
| JPWO2022270523A1 (da) | 2021-06-23 | 2022-12-29 | ||
| CN117460532A (zh) | 2021-06-23 | 2024-01-26 | 东丽株式会社 | 用于癌的治疗和/或预防的药品 |
| WO2023008459A1 (ja) | 2021-07-27 | 2023-02-02 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| EP4378477A1 (en) | 2021-07-27 | 2024-06-05 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| JPWO2023008462A1 (da) | 2021-07-27 | 2023-02-02 | ||
| JPWO2023033129A1 (da) | 2021-09-03 | 2023-03-09 | ||
| WO2024005123A1 (ja) * | 2022-06-30 | 2024-01-04 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698396A (en) | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
| WO2001032910A2 (en) | 1999-10-29 | 2001-05-10 | Human Genome Sciences, Inc. | 27 human secreted proteins |
| US20030118599A1 (en) | 1999-04-02 | 2003-06-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| RU2234942C2 (ru) | 1998-07-14 | 2004-08-27 | Корикса Корпорейшн | Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид |
| IL140845A0 (en) | 1998-07-14 | 2002-02-10 | Corixa Corp | Compositions for therapy and diagnosis of prostate cancer |
| US6969518B2 (en) | 1998-12-28 | 2005-11-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| WO2000052204A2 (en) | 1999-02-22 | 2000-09-08 | Orntoft Torben F | Gene expression in bladder tumors |
| US6444425B1 (en) | 1999-04-02 | 2002-09-03 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
| WO2000060077A2 (en) | 1999-04-02 | 2000-10-12 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| AU2001261007A1 (en) | 2000-03-29 | 2001-10-08 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US20040029114A1 (en) | 2001-01-24 | 2004-02-12 | Eos Technology, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
| RU2306952C2 (ru) | 2001-01-31 | 2007-09-27 | Байоджен Айдек Инк. | Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами |
| WO2002078524A2 (en) | 2001-03-28 | 2002-10-10 | Zycos Inc. | Translational profiling |
| WO2002083070A2 (en) | 2001-04-10 | 2002-10-24 | Corixa Corporation | Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
| EP1516049A4 (en) | 2001-05-11 | 2006-01-11 | Corixa Corp | COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF LUNG CANCER |
| US20030190640A1 (en) | 2001-05-31 | 2003-10-09 | Mary Faris | Genes expressed in prostate cancer |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| US20040258678A1 (en) | 2002-02-22 | 2004-12-23 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US20050003390A1 (en) | 2002-05-17 | 2005-01-06 | Axenovich Sergey A. | Targets for controlling cellular growth and for diagnostic methods |
| US20040126379A1 (en) | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
| WO2004047728A2 (en) | 2002-11-26 | 2004-06-10 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| WO2004076682A2 (en) | 2003-02-26 | 2004-09-10 | Surromed, Inc. | Targets for controlling cellular growth and for diagnostic methods |
| AU2004235382A1 (en) | 2003-04-29 | 2004-11-11 | Wyeth | Methods for diagnosing AML and MDS differential gene expression |
| WO2005005601A2 (en) | 2003-06-09 | 2005-01-20 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| US20070048738A1 (en) | 2003-07-14 | 2007-03-01 | Mayo Foundation For Medical Education And Research | Methods and compositions for diagnosis, staging and prognosis of prostate cancer |
| US20050032113A1 (en) | 2003-07-17 | 2005-02-10 | Mitsubishi Pharma Corporation | Membrane protein library for proteome analysis and method for preparing same |
| WO2005116076A2 (en) | 2004-01-26 | 2005-12-08 | Debiovision Inc. | Neoplasm-specific polypeptides and their uses |
| WO2005090407A1 (en) | 2004-03-19 | 2005-09-29 | Imclone Systems Incorporated | Human anti-epidermal growth factor receptor antibody |
| WO2005100998A2 (en) | 2004-04-16 | 2005-10-27 | Europroteome Ag | Membrane markers for use in cancer diagnosis and therapy |
| WO2006002378A2 (en) | 2004-06-23 | 2006-01-05 | Avalon Pharmaceuticals | Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods |
| RU2438705C2 (ru) | 2005-01-21 | 2012-01-10 | Дженентек, Инк. | Введение фиксированных доз her-антител |
| JP5006802B2 (ja) | 2005-02-18 | 2012-08-22 | チルドレンズ メディカル センター コーポレイション | 上皮由来の癌診断および予後診断のためのバイオマーカーとしてのＣｙｒ６１ |
| NZ560976A (en) | 2005-03-11 | 2011-06-30 | Univ Johns Hopkins | Biomarkers for ovarian cancer and endometrial cancer: hepcidin |
| JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| US8014957B2 (en) | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
| US8211634B2 (en) | 2006-02-14 | 2012-07-03 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
| US20080131428A1 (en) * | 2006-02-24 | 2008-06-05 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| US20100015724A1 (en) | 2006-08-17 | 2010-01-21 | Peter Hornbeck | Lysine acetylation sites |
| US20080107668A1 (en) | 2006-08-30 | 2008-05-08 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| WO2008031041A2 (en) | 2006-09-07 | 2008-03-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Melanoma gene signature |
| WO2008059252A2 (en) | 2006-11-15 | 2008-05-22 | Oxford Biomedica (Uk) Limited | Methods and composition fro t cell receptors which recognize 5t4 antigen |
| DK3106874T3 (da) | 2007-10-25 | 2020-06-02 | Toray Industries | Fremgangsmåde til detektering af cancer |
| JP5663834B2 (ja) | 2008-03-14 | 2015-02-04 | 東ソー株式会社 | 遺伝子組換え抗体の製造方法 |
| CN104888232B (zh) | 2008-03-18 | 2019-05-10 | 健泰科生物技术公司 | 抗her2抗体-药物偶联物和化疗剂的组合，及使用方法 |
| PT2322221E (pt) * | 2008-08-05 | 2014-09-19 | Toray Industries | Composição farmacêutica para tratamento e prevenção de cancro |
| BR122020027042B1 (pt) | 2008-08-05 | 2022-11-08 | Toray Industries, Inc | Uso de um agente indutor de imunidade, uso de um polipeptídeo e uso de um vetor recombinante |
| RU2519089C2 (ru) | 2008-08-05 | 2014-06-10 | Торэй Индастриз, Инк. | Способ обнаружения злокачественных опухолей |
| US8420348B2 (en) | 2009-08-19 | 2013-04-16 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Antibodies for the detection of integrin complexes in FFPE material |
| CA2773240C (en) | 2009-09-22 | 2015-11-10 | Volker Sandig | Process for producing molecules containing specialized glycan structures |
| RU2418587C1 (ru) * | 2010-01-21 | 2011-05-20 | Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО "НижГМА Росздрава") | Способ лечения злокачественных опухолей головного мозга |
| HUE030103T2 (en) | 2010-02-04 | 2017-04-28 | Toray Industries | A pharmaceutical composition for the treatment and / or prevention of cancer |
| ES2691738T3 (es) | 2010-02-04 | 2018-11-28 | Toray Industries, Inc. | Agente farmacéutico para el tratamiento y/o la prevención de cáncer |
| CA2788718C (en) | 2010-02-04 | 2019-05-21 | Shinichi Kobayashi | Caprin-1 antibody for treating and/or preventing cancer |
| MX340017B (es) | 2010-02-04 | 2016-06-22 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| MX342291B (es) | 2010-02-04 | 2016-09-23 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| WO2011096517A1 (ja) | 2010-02-04 | 2011-08-11 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| WO2012005550A2 (ko) | 2010-07-08 | 2012-01-12 | 강원대학교산학협력단 | 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법 |
| AU2011284908B2 (en) | 2010-07-26 | 2015-05-21 | Centre National De La Recherche Scientifique (Cnrs) | Methods and compositions for liver cancer therapy |
| PL2740489T3 (pl) | 2011-08-04 | 2017-06-30 | Toray Industries, Inc. | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka trzustki |
| BR112014002616B1 (pt) | 2011-08-04 | 2022-01-18 | Toray Industries, Inc | Método para detectar câncer pancreático |
| HUE033149T2 (en) | 2011-08-04 | 2017-11-28 | Toray Industries | A pharmaceutical composition for the treatment and / or prevention of cancer |
| BR112014023937A2 (pt) | 2012-03-30 | 2018-04-17 | Toray Industries | composição farmacêutica, agente farmacêutico de combinação e método de tratamento |
| HUE036425T2 (hu) * | 2012-03-30 | 2018-07-30 | Toray Industries | Gyógyászati készítmény epehólyagrák kezelésére és/vagy megelõzésére |
-
2012
- 2012-08-03 HU HUE12820596A patent/HUE033149T2/en unknown
- 2012-08-03 DK DK17163690.5T patent/DK3351630T3/da active
- 2012-08-03 EP EP12820596.0A patent/EP2740796B1/en active Active
- 2012-08-03 US US14/236,793 patent/US9273128B2/en active Active
- 2012-08-03 BR BR112014002608A patent/BR112014002608A2/pt not_active Application Discontinuation
- 2012-08-03 ES ES12820596.0T patent/ES2634249T3/es active Active
- 2012-08-03 HU HUE17163690A patent/HUE047006T2/hu unknown
- 2012-08-03 JP JP2012543824A patent/JP6070191B2/ja active Active
- 2012-08-03 CA CA2844042A patent/CA2844042C/en active Active
- 2012-08-03 AU AU2012290957A patent/AU2012290957B2/en active Active
- 2012-08-03 EP EP17163690.5A patent/EP3351630B1/en active Active
- 2012-08-03 MX MX2014001375A patent/MX351682B/es active IP Right Grant
- 2012-08-03 RU RU2014108044A patent/RU2641260C2/ru not_active Application Discontinuation
- 2012-08-03 PT PT128205960T patent/PT2740796T/pt unknown
- 2012-08-03 PT PT171636905T patent/PT3351630T/pt unknown
- 2012-08-03 ES ES17163690T patent/ES2763122T3/es active Active
- 2012-08-03 PL PL17163690T patent/PL3351630T3/pl unknown
- 2012-08-03 PL PL12820596T patent/PL2740796T3/pl unknown
- 2012-08-03 DK DK12820596.0T patent/DK2740796T3/da active
- 2012-08-03 WO PCT/JP2012/069862 patent/WO2013018894A1/ja active Application Filing
- 2012-08-03 KR KR1020147005881A patent/KR101979208B1/ko active IP Right Grant
- 2012-08-03 CN CN201280038471.0A patent/CN103717740B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014002608A2 (pt) | 2018-02-20 |
| CA2844042C (en) | 2019-06-18 |
| ES2634249T3 (es) | 2017-09-27 |
| EP2740796B1 (en) | 2017-05-17 |
| EP3351630B1 (en) | 2019-10-16 |
| EP3351630A1 (en) | 2018-07-25 |
| HUE033149T2 (en) | 2017-11-28 |
| WO2013018894A1 (ja) | 2013-02-07 |
| PL3351630T3 (pl) | 2020-05-18 |
| EP2740796A1 (en) | 2014-06-11 |
| CA2844042A1 (en) | 2013-02-07 |
| HUE047006T2 (hu) | 2020-04-28 |
| RU2014108044A (ru) | 2015-09-10 |
| ES2763122T3 (es) | 2020-05-27 |
| PT3351630T (pt) | 2019-12-30 |
| JPWO2013018894A1 (ja) | 2015-03-05 |
| EP2740796A4 (en) | 2015-04-22 |
| DK3351630T3 (da) | 2020-01-02 |
| MX351682B (es) | 2017-10-25 |
| CN103717740B (zh) | 2015-10-21 |
| PL2740796T3 (pl) | 2017-10-31 |
| KR101979208B1 (ko) | 2019-05-16 |
| AU2012290957A1 (en) | 2014-03-20 |
| US20140186359A1 (en) | 2014-07-03 |
| US9273128B2 (en) | 2016-03-01 |
| AU2012290957B2 (en) | 2017-04-20 |
| KR20140054185A (ko) | 2014-05-08 |
| JP6070191B2 (ja) | 2017-02-01 |
| PT2740796T (pt) | 2017-07-26 |
| CN103717740A (zh) | 2014-04-09 |
| RU2641260C2 (ru) | 2018-01-16 |
| MX2014001375A (es) | 2014-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2740796T3 (da) | Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer | |
| AU2013223143B2 (en) | Pharmaceutical composition for treatment and/or prevention of cancer | |
| DK2740794T3 (da) | Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer | |
| DK2740798T3 (da) | Lægemiddelsammensætning til cancerbehandling og/eller forebyggelse | |
| DK2740795T3 (da) | Lægemiddelsammensætning til behandling og/eller forebyggelse af cancer | |
| DK2818483T3 (da) | Medicinsk sammensætning til behandling og/eller forebyggelse af cancer | |
| DK2740793T3 (da) | Lægemiddelsammensætning til cancerbehandling og/eller -forebyggelse | |
| AU2013223137B2 (en) | Pharmaceutical composition for treatment and/or prevention of cancer | |
| EP2824114B1 (en) | Pharmaceutical composition for treatment of cancer |